23-December-2010

Novartis submits Bexsero®, a multi-component meningococcal B vaccine, for regulatory review in Europe

 

 

04-November-2010

New data show potential for Novartis Meningitis B vaccine (4CMenB) candidate to cover majority of diverse meningococcal serogroup B strains

 

 

25-October-2010

Phase III data show that Novartis meningococcal vaccine Menveo® demonstrated robust immunogenicity in infants

 

 

22-October-2010

Novartis Phase III study indicates MF59® adjuvanted influenza vaccine, Fluad®, is 75 percent more efficacious than studied non-adjuvanted vaccines in young children

 

 

07-October-2010

Novartis announces agreement to develop influenza vaccines using revolutionary 'synthetic genomics' technology

 

 

24-September-2010

Novartis obtains CHMP positive opinion for its investigational pre-pandemic influenza vaccine Aflunov® to help protect against (H5N1) avian influenza

 

 

12-September-2010

Novartis Phase III study shows meningococcal B vaccine candidate could be first to provide broad coverage against deadly disease

 

 

29-Jul-2010

Novartis Vaccines begins shipment of seasonal influenza vaccine Fluvirin® to U.S. market to help protect ahead of 2010-2011 flu season

 

 

31-Mar-2010

UK Media Release: New vaccine can protect travellers against four types of meningitis

 

 

18-Mar-2010

Novartis receives approval in the European Union for Menveo®, first quadrivalent conjugate vaccine in the EU to help prevent meningococcal disease

 

 

22-Feb-2010

Novartis receives FDA approval of Menveo®, a vaccine to prevent meningococcal disease

 

 

20-Jan-2010

Novartis Receives Regulatory Approval in Japan for Celtura®, a Cell Culture-Based Influenza A(H1N1) 2009 Pandemic Vaccine